Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

HeraMED Ltd. (HMD) Share Price & Analysis

4 Followers

HMD Stock Chart & Stats

A$0.04-A$0.00(-5.41%)
At close: 4:00 PM GMT+11
AU$0.035AU$0.04AU$0.045Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
AUD 0.04 - AUD 0.04
52-Week Range
AUD 0.03 - AUD 0.06
Previous Close
AUD 0.04
Volume
N/A
Average Volume (3M)
334.92K
Market Cap
AUD 42.87M
Enterprise Value
AUD 39.94M
Total Cash (Recent Filing)
AUD 2.03M
Total Debt (Recent Filing)
AUD 0
Price to Earnings (P/E)
―
Beta
1.20
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Gross Margin

The move from negative gross margins in 2020–2022 to roughly 60% in 2023–2024 shows that HeraMED’s offerings can generate positive gross profit. If maintained, this improvement provides a stronger base for covering operating costs and converting revenue growth into better earnings over time.

Deleveraged Balance Sheet

Zero debt materially reduces interest obligations and refinancing exposure compared with the company’s 2021 position, when debt was elevated and equity was negative. Positive equity also provides a more stable capital structure, although the remaining cushion is small relative to ongoing losses.

Focused Digital Health Model

A focused digital health model targeting maternity and broader female health needs gives HeraMED a clearly defined operating purpose and product domain. Concentration in a specific healthcare use case can support consistent solution development and customer relevance as the company builds its business.

Bears Say

Revenue Contraction

Recent revenue contraction and historical volatility indicate that commercial expansion has not yet become dependable. A shrinking or inconsistent top line limits operating leverage, makes fixed costs harder to absorb, and reduces the company’s ability to fund product development and scale from internally generated growth.

Persistent Operating Losses

Persistent operating and net losses show that improved gross margin has not translated into a sustainable earnings model. Continued losses can consume the company’s reduced equity base, constrain investment capacity, and make future financial stability dependent on achieving substantial operating improvement.

Ongoing Cash Burn

Negative operating and free cash flow across every reported year demonstrates that the business has not yet funded its operations through recurring cash generation. Even with burn improving in 2025, continued consumption increases funding pressure and leaves less flexibility to invest in growth or absorb setbacks.

HeraMED Ltd. News

HMD FAQ

What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest share price was AU$0.03 and its highest was AU$0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is AU$42.87M.
When is HeraMED Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.001 earnings per share for the quarter.
Is HeraMED Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,158,636,600 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -AU$0.001 in its last earnings report. Following the earnings report the stock price went down -2.778%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in AU:HMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology